Sorafenib/Regorafenib and lapatinib interact to kill CNS tumor cells

Journal of Cellular Physiology

Volumn 230, Issue 1, 2015, Pages 131-139

  Hamed, Hossein A ^a   Tavallai, Seyedmehrad ^a   Grant, Steven ^a   Poklepovic, Andrew ^a   Dent, Paul ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOPHAGY PROTEIN 5; BECLIN 1; CASPASE 9; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; FLICE INHIBITORY PROTEIN; LAPATINIB; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN BCL XL; PROTEIN P62; REGORAFENIB; SORAFENIB; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; ATG5 PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; BECN1 PROTEIN, HUMAN; CARBANILAMIDE DERIVATIVE; CFLAR PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; FADD PROTEIN, HUMAN; FAS ANTIGEN; FAS PROTEIN, HUMAN; LAMP2 PROTEIN, HUMAN; MAP1LC3A PROTEIN, HUMAN; MAP2K1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; MTOR PROTEIN, HUMAN; NICOTINAMIDE; P62 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL X; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PTEN PROTEIN, HUMAN; PYRIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; RNA BINDING PROTEIN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; AUTOPHAGY; CELL DEATH; CYTOTOXICITY; GLIOBLASTOMA CELL LINE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL DESTRUCTION; ANALOGS AND DERIVATIVES; ANOIKIS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BRAIN NEOPLASMS; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; GLIOBLASTOMA; HUMAN; METABOLISM; TUMOR CELL LINE; UNFOLDED PROTEIN RESPONSE;

ANOIKIS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; BRAIN NEOPLASMS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 9; CELL LINE, TUMOR; DRUG SYNERGISM; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; GLIOBLASTOMA; HUMANS; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 2; MAP KINASE KINASE 1; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; PYRIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA-BINDING PROTEINS; TOR SERINE-THREONINE KINASES; UNFOLDED PROTEIN RESPONSE;

EID: 84910046422     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24689     Document Type: Article

References (26)

1. Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, Sasayama T, James CD, Kornblum HI, Cloughesy TF, Cavenee WK, Bensinger SJ, Mischel PS. 2013. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov 3:534-547.
2. Bareford MD, Hamed HA, Allegood J, Cruickshanks N, Poklepovic A, Park MA, Ogretmen B, Spiegel S, Grant S, Dent P. 2012. Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling. Cancer Biol Ther 13:793-803.
3. Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, Eulitt P, Hubbard N, Tye G, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S, Dent P. 2011. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res 71:4955-4967.
4. Booth L, Cruickshanks N, Ridder T, Chen CS, Grant S, Dent P. 2012. OSU-03012 interacts with lapatinib to kill brain cancer cells. Cancer Biol Ther 13:1501-1511.
5. Carr BI, D'Alessandro R, Refolo MG, Iacovazzi PA, Lippolis C, Messa C, Cavallini A, Correale M, Di Carlo A. 2013. Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro. J Cell Physiol 228:1344-1350.
6. Cruickshanks N, Hamed HA, Booth L, Tavallai S, Syed J, Sajithlal GB, Grant S, Poklepovic A, Dent P. 2013. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy. Cancer Biol Ther 14:982-996.
7. Cruickshanks N, Tang Y, Booth L, Hamed H, Grant S, Dent P. 2012. Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress. Mol Pharmacol 82:1217-1229.
8. Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, Francis P, Cheiken R, Elting J, McNabola A, Wilkie D, Petrenciuc O, Chen EX. 2007. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 25:3766-3773.
9. Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, Dang J, Yang H, Tanaka K, Oba-Shinjo SM, Uno M, Inda MM, Wykosky J, Bachoo RM, James CD, DePinho RA, Vandenberg SR, Zhou H, Marie SK, Mischel PS, Cavenee WK, Furnari FB. 2012. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc Natl Acad Sci USA 109:14164-14169.
10. Gong H, Kovar JL, Cheung L, Rosenthal EL, Olive DM. 2013. A comparative study of affibody, panitumumab, and EGF for near-infrared fluorescence imaging of EGFR-and EGFRvIIIexpressing tumors. Cancer Biol Ther 15:185-193.
11. Hotte SJ, Hirte HW. 2002. BAY 43-9006: Early clinical data in patients with advanced solid malignancies. Curr Pharm Des 8:2249-2253.
12. Martin AP, Park MA, Mitchell C, Walker T, Rahmani M, Thorburn A, Häussinger D, Reinehr R, Grant S, Dent P. 2009. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol Pharmacol 76:327-341.
13. Omuro A, DeAngelis LM. 2013. Glioblastoma and other malignant gliomas: A clinical review. JAMA 310:1842-1850.
14. Park MA, Reinehr R, Häussinger D, Voelkel-Johnson C, Ogretmen B, Yacoub A, Grant S, Dent P. 2010. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol Cancer Ther. 9:2220-2231.
15. Park MA, Zhang G, Martin AP, Hamed H, Mitchell C, Hylemon PB, Graf M, Rahmani M, Ryan K, Liu X, Spiegel S, Norris J, Fisher PB, Grant S, Dent P. 2008. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther 7:1648-1662.
16. Pietrantonio F, Perrone F, Biondani P, Maggi C, Lampis A, Bertan C, Venturini F, Tondulli L, Ferrari D, RicciV,Villa F, BaroneG,BiancoN,Ghidini A, Bossi I, Fanetti G, Di BartolomeoM, de Braud F. 2013. Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy. Cancer Biol Ther 14:1098-1103.
17. Pratz KW, Cho E, Levis MJ, Karp JE, Gore SD, McDevitt M, Stine A, Zhao M, Baker SD, Carducci MA, Wright JJ. 2010. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia. 24:1437-1444.
18. Quatrale AE, Porcelli L, Silvestris N, Colucci G, Angelo A, Azzariti A. 2011. EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Front Biosci 16:1962-1972.
19. Rahmani M, Davis EM, Bauer C, Dent P, Grant S. 2005. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 throughinhibition of translation. J Biol Chem 280:35217-35227.
20. Rahmani M, Davis EM, Crabtree TR, Habibi JR, Nguyen TK, Dent P, Grant S. 2007. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol 27:5499-5513.
21. Ramirez YP, Weatherbee JL, Wheelhouse RT, Ross AH. 2013. Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals (Basel) 6:1475-1506.
22. Reardon DA, Groves MD, Wen PY, Nabors L, Mikkelsen T, Rosenfeld S, Raizer J, Barriuso J, McLendon RE, Suttle AB, Ma B, Curtis CM, Dar MM, de Bono J. 2013. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res 19:900-908.
23. Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR. 2013. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Cancer Treat Rev 39:839-850.
24. Smith MA, Houghton P. 2013. A proposal regarding reporting of in vitro testing results. Clin Cancer Res 19:2828-2833.
25. Valerie K, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S, Dent P. 2007. Radiationinduced cell signaling: inside-out and outside-in. Mol Cancer Ther 6:789-801.
26. Villarroel MC, Pratz KW, Xu L, Wright JJ, Smith BD, Rudek MA. 2012. Plasma protein binding of sorafenib, a multi kinase inhibitor: In vitro and in cancer patients. Invest New Drugs 30:2096-2102.